Journal of Microbiology

The Microbiological Society of Korea (한국미생물학회)
권호 표지

Affinity Maturation of an Anti-Hepatitis B Virus PreS1 Humanized Antibody by Phage Display

  • Yang, Gi-Hyeok (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Yoon, Sun-Ok (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Jang, Myung-Hee (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Hong, Hyo-Jeong (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

In a previous study we generated an anti-Hepatitis B Virus (HBV) preS1 humanized antibody (HzKR127) that showed in vivo HBV-neutralizing activity in chimpanzees. However, the antigen-binding affinity of the humanized antibody may not be sufficient for clinical use and thus affinity maturation is required for better therapeutic efficacy. In this study, phage display technique was employed to increase the affinity of HzKR127. All six amino acid residues (Glu95-Tyr96-Asp97-Glu98-Ala99-Tyr100) in the heavy (H) chain complementary-determining region 3 (HCDR3) of HzKR127 were randomized and phage-displayed single chain Fv (scFv) library was constructed. After three rounds of panning, 12 different clones exhibiting higher antigen-binding activity than the wild type ScFv were selected and their antigen-binding specificity for the preS1 confirmed. Subsequently, five ScFv clones were converted to whole IgG and subjected to affinity determination. The results showed that two clones (B3 and A19) exhibited an approximately 6 fold higher affinities than that of HzKR127. The affinity-matured humanized antibodies may be useful in anti-HBV immunotherapy.

Keywords

References

  1. Bhatnager, P.K., E. Papas, H.E. Blum, D.R. Milich, D. Nitecki, M.J. Kareb, and G.N. Vyas. 1982. Immune response to synthetic peptide analogues of HBsAg specific for the a detertminant. Proc. Natl. Acad. Sci. USA 79, 4723-4727
  2. Burton, D.R., C.F. Barbas, 3rd, M.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134
  3. Dreesman, G.R., Y. Sanchez, I. Ionescu-Matiu, J.T. Sparrow, H.R. Six, D.L. Peterson, F.B. Hollinger, and J.L. Melnick. 1982. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature 295, 158-160 https://doi.org/10.1038/295158a0
  4. Griffiths, A.D., S.C. Williams, O. Hartley, I.M. Tomlinson, P. Waterhouse, W.L. Crosby, R.E. Kontermann, P.T. Jones, N.M. Low, T.J. Allison, T.D. Prospero, H.R. Hoogenboom, A. Nissim, J.P.L. Cox, J.L. Harrison, M. Zaccolo, E. Gherardi, and G. Winter. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260
  5. Heermann, K.H., U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten, and W.H. Gerlich. 1984. Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 52, 396-402
  6. Heermann, K.H., F. Kruse, M. Seifer, and W.H. Gerlich. 1987. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments. Intervirology 28, 14-25 https://doi.org/10.1159/000149993
  7. Hong, H.J., C.J. Ryu, H. Hur, S. Kim, H.K. Oh, M.S. Oh, and S.Y. Park. 2004. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318, 134-138 https://doi.org/10.1016/j.virol.2003.09.014
  8. Horton, R.M., H.D. Hunt, S.N. Ho, J.K. Pullen, and L.R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77, 61 https://doi.org/10.1016/0378-1119(89)90359-4
  9. Itoh, Y., E. Takai, H. Ohnuma, K. Kitayima, F. Tsuda, A. Machida, S. Mishiro, T. Nakamura, Y. Miyakawa, and M. Mayumi. 1986. A synthetic peptide vaccine involving the product of the preS2 region of hepatitis B virus: protective efficacy in chimpanzees. Proc. Natl. Acad. Sci. USA 83, 9174-9178
  10. Kim, H.S and H.J. Hong, 1995. Efficient expression, purificaion and characterization of hepatitis B virus perS1 protein from Escherichia coli. Biotechnol. Lett. 17, 871-876 https://doi.org/10.1007/BF00129021
  11. Komissarov, A.A., M.T. Marchbank, M.J. Calcutt, T.P. Quinn, and S.L. Deutscher. 1997. Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity- determining region 3 residues in antigen interaction. J. Biol. Chem. 272, 26864-26870 https://doi.org/10.1074/jbc.272.43.26864
  12. Krykbaev, R.A., W.R. Liu, P.D. Jeffrey, and M.N. Margolies. 2001. Phage display-selected sequences of the heavy-chain CDR3 loop of the anti-digoxin antibody 26-10 define a high affinity binding site for position 16-substituted analogs of digoxin. J. Biol. Chem. 276, 8149-8158 https://doi.org/10.1074/jbc.M008108200
  13. Maeng, C.Y., C.J. Ryu, P. Gripon, C. Guguen-Guillouzo, and H.J. Hong. 2000. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. Virology 270, 9-16 https://doi.org/10.1006/viro.2000.0250
  14. Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581
  15. Milich, D.R. 1987. Immunological response to pre-S antigens of the hepatitis B virus. Viral. Immunol. 1, 83-96 https://doi.org/10.1089/vim.1987.1.83
  16. Neurath, A.R., S.B. Kent, N. Strick, and K. Parker. 1986. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429-436 https://doi.org/10.1007/s12275-007-0163-y
  17. Neurath, A.R., B. Seto, and N. Strick. 1989. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 7, 234-236 https://doi.org/10.1016/0264-410X(89)90235-1
  18. Oh, M.S., K.S. Kim, Y.K. Jang, C.Y. Maeng, S.H. Min, M.H. Jang, S.O. Yoon, J.H. Kim, and H.J. Hong. 2003. A new epitope tag from hepatitis B virus preS1 for immunodetection, localization and affinity purification of recombinant proteins. J. Immunol. Meth. 283, 77 https://doi.org/10.1016/j.jim.2003.08.010
  19. Persing, D.H., H.E. Varmus, and D. Ganem. 1986 Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science 234, 1388-1391 https://doi.org/10.1126/science.3787251
  20. Pontisso, P., M.G. Ruvoletto, W.H. Gerlich, K.H. Heermann, R. Bardini, and A. Alberti. 1989. Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology 173, 522-530 https://doi.org/10.1016/0042-6822(89)90564-3
  21. Ryu, C.J., D.Y. Cho, P. Gripon, H.S. Kim, C. Guguen-Guillouzo, and H.J. Hong. 2000. An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus. J. Virol. 74, 110-116 https://doi.org/10.1128/JVI.74.1.110-116.2000
  22. Shawler, D.L., R.M. Bartholomew, L.M. Smith, and R.O. Dillman. 1985. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135, 1530-1535
  23. Stibbe, W. and W.H. Gerlich. 1983. Structural relationships between minor and major proteins of hepatitis B surface antigen. J. Virol. 46, 626-628
  24. Winter, G., A.D. Griffiths, R.E. Hawkins, and H.R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455 https://doi.org/10.1146/annurev.iy.12.040194.002245
  25. Xu, J.L. and M.M. Davis. 2000. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Cell 13, 37-45